NCT06584123 Molecular Pituitary Imaging Using 18F-FET PET
| NCT ID | NCT06584123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Cambridge |
| Condition | Pituitary Adenoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-09-03 |
| Primary Completion | 2026-09-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-09-03 with a primary completion date of 2026-09-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.
Eligibility Criteria
Inclusion criteria * Participant is willing and able to give informed consent for participation in the study * Male or female, age 18 or above * Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings * Previous 11C-Met-PET/CT Exclusion criteria * Inability to give informed consent * Pregnancy or suspected pregnancy * Inability to lie supine for 30-60 minutes * Patient body habitus above scanner dimensions * Known allergy to intravenous radiographic contrast agents
Contact & Investigator
Mark Gurnell, MD, PhD
PRINCIPAL INVESTIGATOR
Cambridge University Hospitals NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT06584123 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Pituitary Adenoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06584123 currently recruiting?
Yes, NCT06584123 is actively recruiting participants. Contact the research team at jm2267@medschl.cam.ac.uk for enrollment information.
Where is the NCT06584123 trial being conducted?
This trial is being conducted at Cambridge, United Kingdom.
Who is sponsoring the NCT06584123 clinical trial?
NCT06584123 is sponsored by University of Cambridge. The principal investigator is Mark Gurnell, MD, PhD at Cambridge University Hospitals NHS Foundation Trust. The trial plans to enroll 20 participants.